The PFDN6 antibody targets the Prefoldin subunit 6 (PFDN6), a component of the molecular chaperone complex prefoldin. Prefoldin, composed of six subunits (PFDN1-6), assists in nascent protein folding by binding partially unfolded polypeptides and delivering them to the cytosolic chaperonin complex (CCT) for proper folding, particularly for cytoskeletal proteins like actin and tubulin. PFDN6. also known as CGI-101 or HINAP6. is crucial for maintaining proteostasis and cellular function. Dysregulation of prefoldin complexes has been linked to diseases, including cancers and neurodegenerative disorders, where protein misfolding or aggregation occurs.
Antibodies against PFDN6 are essential tools for studying its expression, localization, and interactions in biological systems. They are widely used in techniques such as Western blotting, immunoprecipitation, and immunofluorescence to investigate PFDN6's role in cellular processes, disease mechanisms, or its potential as a biomarker. Commercially available PFDN6 antibodies are typically validated for specificity using knockout controls or siRNA-mediated silencing. Researchers also employ them to explore correlations between PFDN6 levels and pathological conditions, such as tumor progression or neuronal degeneration. Due to prefoldin's conserved structure, cross-reactivity with orthologs in model organisms (e.g., mice, zebrafish) is often confirmed, enabling translational studies.